The Iacocca Family Foundation Boosts Investment in Kineta Inc.’s Autoimmune Program

Published: Jul 19, 2011

SEATTLE--(BUSINESS WIRE)--Kineta, Inc. joined with The Iacocca Family Foundation today to announce second year funding for its investment partnership aimed at speeding development of Kineta’s preclinical autoimmune drug candidate – ShK-186 – with applications for type 1 diabetes mellitus, multiple sclerosis and other autoimmune diseases.

Back to news